Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117946 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL1063199 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL29349956 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL29384797 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL31714182 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL119588 | 1.00 | MDM4 (0.51) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL31369598 | 0.97 | MDM2 (0.53) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL30516252 | 0.95 | PTPN1 (0.54) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL30516240 | 0.95 | PTPN1 (0.54) | MDM4TP53MDM2PTPN1ITGB3 | |
| SCHEMBL30516235 | 0.95 | PTPN1 (0.54) | MDM4TP53MDM2PTPN1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113717246-B | Preparation method of polypeptide heterodimer | 核欣(苏州)医药科技有限公司 | 2025-03-25 | — | — | CN | claimed |
| CN-119529031-A | Cyclic peptide derivative and preparation method and application thereof | 润辉生物技术（威海）有限公司 | 2025-02-28 | — | — | CN | claimed |
| CN-116284236-B | The method comprises the following steps of 18 F-nuclein labeled somatostatin receptor inhibitor probe, preparation method thereof and kit | 中国医学科学院北京协和医院 | 2024-02-20 | — | — | CN | claimed |
| CN-116121754-B | Organic system Al/Mo etching solution, and preparation method and application thereof | 浙江奥首材料科技有限公司 | 2023-11-17 | — | — | CN | claimed |
| CN-116284236-A | The method comprises the following steps of 18 F-nuclein labeled somatostatin receptor inhibitor probe, preparation method thereof and kit | 中国医学科学院北京协和医院 | 2023-06-23 | — | — | CN | claimed |
| CN-112442117-B | Tumor imaging and treating probe targeting follicle-stimulating hormone receptor, and preparation method and application thereof | 复旦大学 | 2022-07-08 | — | — | CN | claimed |
| WO-2026098617-A1 | RADIOPHARMACEUTICAL TARGETING CARBONIC ANHYDRASE IX PROTEIN | 无锡诺宇医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| CN-122036881-A | Somatostatin receptor-targeting compounds and uses thereof | 无锡诺宇医药科技有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260131034-A1 | RADIOPHARMACEUTICALS TARGETING CARBONIC ANHYDRASE IX PROTEINS | NORROY BIOSCIENCE CO LTD (CN) | 2026-05-14 | — | — | US | disclosed |
| US-12616761-B2 | CXCR4-targeting compounds | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-05-05 | — | — | US | disclosed |
| EP-4722229-A1 | ADAPTOR MOLECULES FOR TARGETED CELL IMMUNOTHERAPIES | Universität Zürich (CH) | 2026-04-08 | — | — | EP | disclosed |
| EP-4720097-A1 | PEPTIDES WITH LIPOLYTIC, ANTI-LIPOGENIC, ANTIFIBROTIC AND ANTI-INFLAMMATORY ACTIVITY | Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (ES) | 2026-04-08 | — | — | EP | disclosed |
| US-20260027244-A1 | SILICON-BASED FLUORIDE ACCEPTOR GROUPS FOR RADIOPHARMACEUTICALS | Technische Universität München (DE) | 2026-01-29 | — | — | US | disclosed |
| CN-114315958-A | Compound and application thereof | 北京志道生物科技有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3974563-A1 | CYCLIC PEPTIDES | Chugai Seiyaku Kabushiki Kaisha (JP) | 2022-03-30 | — | — | EP | disclosed |
| CN-106573959-B | Modified cyclic pentapeptides and uses thereof | 慕尼黑工业大学 | 2022-03-25 | — | — | CN | disclosed |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2022-03-22 | — | — | US | disclosed |
| WO-2022052471-A1 | BISPECIFIC FUSION POLYPEPTIDE COMPOUND | 陕西麦科奥特科技有限公司 | 2022-03-17 | — | — | WO | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| WO-2022018185-A1 | GLP-1 AND GIP RECEPTOR CO-AGONISTS | NOVO NORDISK A/S (DK) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131034-A1 | RADIOPHARMACEUTICALS TARGETING CARBONIC ANHYDRASE IX PROTEINS | CA9, CA11, CA12 | MDM4 4599/4885TP53 3128/4885MDM2 4177/4885 |
| US-20260027244-A1 | SILICON-BASED FLUORIDE ACCEPTOR GROUPS FOR RADIOPHARMACEUTICALS | SSTR3, SLC43A1, SSTR1 | MDM4 3474/4885TP53 1042/4885MDM2 2006/4885 |
| US-12616761-B2 | CXCR4-targeting compounds | CXCR4, CXCR2, CXCR3 | MDM4 3817/4885TP53 1733/4885MDM2 3597/4885 |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | MDM4 4779/4885TP53 2714/4885MDM2 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.